Premium
The Competition Commission of India on Monday approved Singapore’s state investment arm Temasek’s move to sell a 3% stake in Intas Pharmaceuticals to Abu Dhabi Investment Authority (Adia). “The commission approves acquisition by Platinum Owl (Adia investor) of 3% of the equity shareholding of Intas,” the CCI said in a tweet. The ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
